Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Support

This activity is supported by an educational grant from Genentech, Inc.

Community Practice Connections™: Severe Asthma Through the Ages: Personalized Management for Difficult-to-Treat Children, Adolescents, and Adults

Release Date: May 29, 2020
Expiration Date: May 29, 2021

Activity Overview

This online activity is designed to provide an overview of guideline-supported recommendations for severe asthma management in children, adolescents, and adults, as well as a discussion about chronic rhinosinusitis with nasal polyps, which is a frequent comorbidity in asthma. The material also covers personalized asthma treatment based on factors including patients’ asthma endotype and phenotype. The multimedia format of this program includes audio commentary from expert thought leaders integrated with text-based elements.

Acknowledgement of Support

This activity is supported by an educational grant from Genentech, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward allergists/immunologists, primary care physicians, nurse practitioners, physician assistants, and other health care professionals involved in the management of asthma.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Review guidelines and recommendations for management of severe asthma in patients across age groups
  • Discuss efficacy, safety, and considerations for patient age in selection of agents for severe asthma
  • Evaluate efficacy and safety of agents for treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and other comorbid conditions of severe/difficult-to-treat asthma

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Reynold A. Panettieri, Jr., MD
Reynold A. Panettieri Jr, MD
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, PA
Science Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor for Translational Medicine and Science Director
Rutgers Institute for Translational Medicine and Science
New Brunswick, NJ

Disclosures: Grant/Research Support: AstraZeneca, MedImmune, RIFM, Equillium, Genentech, OncoArendi Therapeutics, Metera Pharmaceuticals. Consultant: AstraZeneca, MedImmune, RIFM, Equillium, Theravance Biopharma, Avillion. Speakers Bureau: AstraZeneca, Sanofi/Regeneron, Genentech.

Natasha McClure, DNP, RN, CPNP
Natasha McClure, DNP, RN, CPNP
Assistant Professor
Vanderbilt University School of Nursing
Faculty Head of North House, The Martha Rivers Ingram Commons
Nashville, TN

Disclosures: Natasha McClure, DNP, RN, CPNP, has no relevant financial relationships with commercial interests.

Michael E. Wechsler, MD, MMSc
Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, The Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO

Disclosures: Grant/Research Support: AstraZeneca, Sanofi, Regeneron, Teva. Consultant: AstraZeneca, Sanofi, Regeneron, Novartis, Genentech, GlaxoSmithKline, Amgen, Genzyme, Teva, Equillium. Speakers Bureau: GlaxoSmithKline, Sanofi/Regeneron.

PER uses a blinded peer review process.

The peer reviewer discloses the following: Grant Research Support: NINDS; Consultant: Remedy Pharmaceuticals, Biogen; Shareholder: Remedy Pharmaceuticals.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By